Search

Displaying results 3391 - 3400 of 8517 in total
  1. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.

  2. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [L40533] Mitapivat has also been investigated in other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and alpha- and beta-thalassemia. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  3. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement … [L64068,L64069] Unlike existing narcolepsy treatments such as stimulants and sedatives, which manage individual symptoms, oveporexton acts on the underlying orexin deficiency that drives the disorder.

  4. Drug

    Antithrombin III human

    go.drugbank.com/drugs/DB11598
    ApprovedInvestigational

    A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.

  5. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)

    Synonyms: BTS
  6. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

  7. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

  8. Drug

    Hydroxystilbamidine

    go.drugbank.com/drugs/DB14753
    Approved

    Hydroxystilbamidine isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than amphotericin B. Hydroxystilbamidine ...

  9. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".

  10. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models